Back to search

Article

Spatial Profiling of Patient-Matched HER2 Positive Gastric Cancer Reveals Resistance Mechanisms to Trastuzumab and Trastuzumab Deruxtecan

2024-11-04

Abstract excerpt

<h4>PURPOSE</h4> HER2-positive gastric cancer (HER2+ GC) exhibits significant intra-tumoral heterogeneity and frequent development of resistance to HER2-targeted therapies. This study aimed to characterize the spatial tumor microenvironment (TME) in HER2+ GC and identify mechanisms of resistance to HER2 blockade including trastuzumab and trastuzumab deruxtecan (T-DXd), with the goal of informing novel therapeutic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3573094f-264c-5ddf-8938-a8d27e6044b0
DOI
10.1101/2024.10.29.24316248
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Spatial Profiling of Patient-Matched HER2 Positive Gastric Cancer Reveals Resistance Mechanisms to Trastuzumab and Trastuzumab DeruxtecanDOI 10.1101/2024.10.29.24316248
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerSemantic proximity
Targeted spatial profiling identifies a CD8A − LARS axis associated with neoadjuvant chemotherapy resistance in triple-negative breast cancerSemantic proximity
Spatial Transcriptomics in Breast Cancer Reveals Tumour Microenvironment-Driven Drug Responses and Clonal Therapeutic HeterogeneitySemantic proximity
Spatial immune ecosystems govern therapeutic response in HER2-low breast cancerSemantic proximity
Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancerSemantic proximity
The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profilingSemantic proximity
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialSemantic proximity
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity
Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity
Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity
The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cellsSemantic proximity
EphB4 Inhibition Regulates Tumor Microenvironment by Promoting Immunogenic Cell Death Effector Mechanism in Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.